403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Why Is ARTL Stock Soaring Pre-Market Today?
(MENAFN- AsiaNet News)
Artelo Biosciences Inc. (ARTL) on Wednesday announced that it has secured a fully funded glaucoma study following an agreement with Glaucoma UK and the HSC R & D Division.
The study will evaluate the effects of Artelo's peripherally selective synthetic cannabinoid, ART27.13, in patients with glaucoma or ocular hypertension.
Artelo Biosciences shares were up more than 40% in Wednesday's pre-market trade. Retail sentiment on Stocktwits around the company trended in the 'extremely bullish' territory with message volumes at 'high' levels at the time of writing.
Get updates to this story developing directly on Stocktwits.
For updates and corrections, email newsroom[at]stocktwits[dot]com.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment